A "protease activation cascade" in the pathogenesis of Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 924, Issue , 2000, Pages 117-131

  Nixon, Ralph A ^a,b  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Apoptosis; Calpains; Cathespins; Endocytosis; Lysosomes; Tau; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; CALPAIN; CALPASTATIN; CATHEPSIN; PROTEINASE;

ALZHEIMER DISEASE; APOPTOSIS; CELL AGING; CONFERENCE PAPER; ENDOCYTOSIS; ENDOSOME; ENVIRONMENTAL FACTOR; HEREDITY; LYSOSOME; NERVE CELL DEGENERATION; NEUROPATHOLOGY; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

EID: 0034507918     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb05570.x     Document Type: Conference Paper

References (125)

1. Calpains in the pathogenesis of Alzheimer's disease
2. The neuronal endosomal-lysosomal system in Alzheimer's disease
3. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease
4. Lp82 is the dominant form of calpain in young mouse lens
5. Evidence for the involvement of calpain in cataractogenesis in Shumiya cataract rat (SCR)
6. Band 3 protein degradation by calpain is enhanced in erythrocytes of old people
7. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors
8. Changes in brain protease activity in aging
9. Calpain II activity and calpastatin content in brain regions of 3- and 24-month-old rats
10. Calpain from rat intestinal epithelial cells: Age-dependent dynamics during cell differentiation
11. Animal models for human diseases of the brain
12. Age-related increase in a cathepsin D-like protease that degrades brain microtubule-associated proteins
13. Increased expression of cathepsins E and D in neurons of the aged rat brain and their colocalization with lipofuscin and carboxy-terminal fragments of Alzheimer amyloid precursor protein
14. In vivo perturbation of lysosomal function promotes neurodegeneration in the PS/APP mouse model of Alzheimer's disease pathology
15. Anomalous accumulation of tau and ubiquitin immunoreactivities in rat brain caused by protease inhibition and by normal aging: A clue to PHF pathogenesis?
16. The lysosomal system in neuronal cell death: A review
17. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L
18. Changes in the concentrations of tau and other structural proteins in the brains of aged mice
19. Lysosomal dysfunction reduces brain-derived neurotrophic factor expression
20. Suppression of cathepsins B and L causes a proliferation of lysosomes and the formation of meganeurites in hippocampus
21. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus
22. Endocytic pathway abnormalities precede beta-amyloid deposition in sporadic Alzheimer's disease: Differential effects of APOE genotype and presenilin mutations
23. Accelerated A-beta generation in AD models of lysosomal system upregulation
24. Alzheimer's A beta (1-42) is generated in the endoplasmic reticulum/intermediate compartment of NT2N cells
25. Non-selective autophagy
26. Properties of the endosomal-lysosomal system in the human central nervous system: Disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease
27. Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: Evidence for early up-regulation of the endosomal-lysosomal system
28. Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: Evidence for a neuronal origin
29. Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease
30. Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles
31. The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: A review
32. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease
33. Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease
34. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain
35. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease
36. Immunodetection of cathepsin D in neuritic plaques found in brains of patients with dementia of Alzheimer type
37. The endosomal-lysosomal system of neurons: New roles
38. Early neurodegenerative alterations in the cerebral cortex during normal aging and Alzheimer's disease
39. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease
40. Difference between the tau protein of Alzheimer paired helical filament core and normal tau revealed by epitope analysis of monoclonal antibodies 423 and 7.51
41. Neurodegenerative tauopathies: Human disease and transgenic mouse models
42. Phosphorylation of tau in situ: Inhibition of calcium-dependent proteolysis
43. Calcium influx into human neuroblastoma cells induces ALZ-50 immunoreactivity: Involvement of calpain-mediated hydrolysis of protein kinase C
44. Alzheimer's neurofibrillary tangles contain unique epitopes and epitopes in common with the heat-stable microtubule associated proteins tau and MAP2
45. Intracellular A beta 1-42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells
46. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments
47. +requiring proteinase
48. Neurotoxicity induces cleavage of p35 to p25 by calpain
49. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25
50. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
51. Differential sensitivity to proteolysis by brain calpain of adult human tau, fetal human tau and PHF-tau
52. FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion
53. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: A potential molecular basis for neuronal degeneration
54. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors
55. Increased proteolytic activity in erythrocytes from patients with Alzheimer's disease
56. Endocytic alterations in human preclinical AD and a trisomic mouse model of Down syndrome: Implications for beta-amyloidogenesis
57. Amyloid beta-peptide is produced by cultured cells during normal metabolism
58. Evidence that production and release of amyloid beta-protein involves the endocytic pathway
59. Expression of beta-amyloid precursor protein-CD3 gamma chimeras to demonstrate the selective generation of amyloid beta (1-40) and amyloid beta (1-42) peptides within secretory and endocytic compartments
60. The pathway of alphabeta 42 production in APP with codon 717 mutation
61. Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including A-beta 42
62. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
63. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: Neuropathologic evidence for a mechanism of increased beta-amyloidogenesis
64. Candidate gamma-secretases in the generation of the carboxyl terminus of the Alzheimer's disease beta A4 amyloid: Possible involvement of cathepsin D
65. Identification of beta-secretase-like activity using a mass spectrometry-based assay system
66. Processing of the prebeta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation
67. Cathepsin D displays in vitro beta-secretase-like specificity
68. Lysosomal processing of amyloid precursor protein to A beta peptides: A distinct role for cathepsin S
69. A possible role for cathepsins D, E, and B in the processing of beta-amyloid precursor protein in Alzheimer's disease
70. Mannose 6-phosphate receptor dependent secretion of lysosomal enzymes
71. Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D
72. Activation of caspase-3 and apoptosis in cerebellar granule cells
73. Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene
74. Association between the low density lipoprotein receptor-related protein (L RP) and Alzheimer's disease
75. The human FE65 gene: Genomic structure and an intronic biallelic polymorphism associated with sporadic dementia of the Alzheimer type
76. Alpha-2 macroglobulin is genetically associated with Alzheimer disease
77. Missense polymorphism (C/T224) in the human cathepsin D pro-fragment determined by polymerase chain reaction-single strand conformational polymorphism analysis and possible consequences in cancer cells
78. Genetic polymorphism of cathepsin D is strongly associated with the risk for developing sporadic Alzheimer's disease
79. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease
80. The cystatin C gene as a novel genetic risk factor for late onset Alzheimer's disease
81. Molecular interactions between presenilin and calpain: Inhibition of m-calpain protease activity by presenilin-1, 2 and cleavage of presenilin-1 by m-, mu-calpain
82. The calpain hypothesis of neurodegeneration: Evidence for a common cytotoxic pathway
83. Calpain I activation in rat hippocampal neurons in culture is NMDA receptor selective and not essential for excitotoxic cell death
84. Role of calpain I in excitatory amino acid induced degenerative structural changes
85. Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors
86. Role of calpain- and interleukin-1 beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippocampal neurons in culture
87. Calpain and caspase: Can you tell the difference?
88. Activation of calpain I converts excitotoxic neuron death into a caspase-independent cell death
89. Direct cleavage by the calcium-activated protease calpain can lead to inactivation of caspases
90. Maitotoxin induces calpain but not caspase-3 activation and necrotic cell death in primary septo-hippocampal cultures
91. Reovirus-induced apoptosis is preceded by increased cellular calpain activity and is blocked by calpain inhibitors
92. Calpain and calpastatin regulate neutrophil apoptosis
93. + influx upregulate calpain and induce apoptosis in PC12 cells
94. Implication of calpain in caspase activation during B cell clonal deletion
95. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation
96. Ethanol-impaired hepatic protein trafficking: Concepts from the asialoglycoprotein receptor system
97. Participation of a cathepsin L-type protease in the activation of caspase-3
98. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, Fas/APO-1 and TNF-alpha
99. Regulation of a novel pathway for cell death by lysosomal aspartic and cysteine proteinases
100. Inhibition of cathepsin D prevents free-radical-induced apoptosis in rat cardiomyocytes
101. Cathepsin D targeted by acid sphingomyelinase-derived ceramide
102. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts
103. Cell death induced by peroxidized low-density lipoprotein: Endopepsis
104. Oxidant-induced apoptosis: A consequence of lethal lysosomal leak?
105. Oxidative stress causes relocation of the lysosomal enzyme cathepsin D with ensuing apoptosis in neonatal rat cardiomyocytes
106. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice
107. Lysosomal release of cathepsin D precedes relocation of cytochrome c and loss of mitochondrial transmembrane potential during apoptosis induced by oxidative stress
108. Determinants of the apoptotic response to lysosomal photodamage
109. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta 1-42 pathogenesis
110. Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation
111. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: A novel strategy for neuroprotection based on "calpain-cathepsin hypothesis."
112. Cellular pathology of lysosomal storage disorders
113. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models
114. Adult onset lysosomal storage disease in a Tibetan terrier: Clinical, morphological and biochemical studies
115. Recent advances in elucidating Niemann-Pick C disease
116. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration
117. A hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein
118. Impaired cerebromicrovascular perfusion: Summary of evidence in support of its causality in Alzheimer's disease
119. The brain's microenvironment, early functional loss and the conversion to Alzheimer's disease
120. Apolipoprotein E and Alzheimer's disease
121. Apolipoprotein E and Alzheimer's disease
122. Comprehensive theory of Alzheimer's disease: Cholesterol effects on membrane receptor trafficking
123. Oxidative metabolism
124. Oxidative stress leading to loss of critical proteases in Alzheimer's disease: An alternative view of the etiology of AD
125. Existing data suggest that Alzheimer's disease is preventable